FDA has stated that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law [3]
As of April 2026, semaglutide (both the 0.25/0.5/1 mg Ozempic pens and the 0.25/0.5/1/1.7/2.4 mg Wegovy pens) remains in shortage, allowing compounding pharmacies to prepare semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act
It can feel overwhelming and confusing to know who to go to when youre contemplating a treatment or procedure
MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer
FCATs Will Reed spoke with Bleecker to discuss how artists, technologists, and everyday
Wang W, Lin W, Hong B, Li X, Zhang M, Zhang L, et al